# Neurogenic Bladder Management After SCI

## Overview
Neurogenic bladder dysfunction is universal after significant spinal cord injury. Primary goals: preserve upper urinary tract (renal function), maintain continence, prevent UTI, maximize independence. Renal failure was historically the leading cause of death in SCI - now preventable with proper management. Bladder management is consistently ranked as a top priority by SCI patients.

## Neuroanatomy of Micturition

### Normal Voiding Physiology
Bladder storage: sympathetic (T11-L2, hypogastric nerve) relaxes detrusor, contracts internal sphincter. Bladder emptying: parasympathetic (S2-S4, pelvic nerve) contracts detrusor. External urethral sphincter: somatic (S2-S4, pudendal nerve) - voluntary control. Pontine micturition center (Barrington's nucleus): coordinates detrusor contraction with sphincter relaxation. Cerebral cortex: voluntary inhibition/initiation of voiding.

### Spinal Cord Injury Effects
Disruption of communication between brain, pontine micturition center, and sacral micturition center. Results depend on level and completeness of injury.

## Classification of Neurogenic Bladder

### Upper Motor Neuron (UMN) Bladder - Suprasacral Lesions
Injury above the sacral micturition center (above S2). Detrusor hyperreflexia (overactive bladder). Spastic external sphincter. Detrusor-sphincter dyssynergia (DSD): simultaneous contraction of detrusor and external sphincter.

High-pressure bladder - dangerous for upper tracts. Small capacity, reflexive emptying. Key risk: elevated detrusor pressures > 40 cmH2O cause vesicoureteral reflux and renal damage.

### Lower Motor Neuron (LMN) Bladder - Sacral/Infrasacral Lesions
Injury at or below S2 (conus medullaris, cauda equina). Detrusor areflexia (flaccid bladder). Decreased sphincter tone. Large capacity, low pressure, overflow incontinence. Incomplete emptying with high post-void residuals. Risk: chronic overdistension, UTI from stasis.

| Feature | UMN Bladder (Suprasacral) | LMN Bladder (Sacral/Infrasacral) |
|---------|--------------------------|----------------------------------|
| Lesion level | Above S2 | At or below S2 |
| Detrusor | Hyperreflexic (overactive) | Areflexic (flaccid) |
| Sphincter | Spastic, DSD | Decreased tone |
| Capacity | Small | Large |
| Pressure | High (dangerous) | Low |
| Emptying pattern | Reflexive, incomplete | Overflow incontinence |
| Key risk | High pressure → renal damage | Overdistension, stasis → UTI |
| Management | CIC + antimuscarinics | CIC ± Credé/Valsalva |

<image>Comparison of upper motor neuron and lower motor neuron neurogenic bladder pathophysiology</image>

## Spinal Shock Phase
Occurs immediately after SCI. Detrusor areflexia regardless of injury level. Duration: days to weeks (up to 6-12 weeks). Management: indwelling catheter initially, transition to intermittent catheterization as soon as medically stable. Bladder reflexes gradually return in UMN lesions.

## Bladder Management Options

### Clean Intermittent Catheterization (CIC)
Gold standard for neurogenic bladder management in SCI. Frequency: every 4-6 hours (target volumes < 500 mL per catheterization). Fluid management: ~2 L/day, evenly distributed. Advantages: mimics normal fill-and-empty cycle, low infection risk, preserves upper tracts.

Patient requirements: adequate hand function (C6-C7 and below), cognitive ability, motivation. Adaptive equipment for patients with limited hand function (e.g., catheter holders, leg bags). Teach clean (not sterile) technique for community use.

### Indwelling Catheterization
Foley (urethral) or suprapubic catheter. Reserved for patients who cannot perform CIC or when CIC is impractical. Complications: higher UTI rates, bladder stones, urethral erosion (Foley), squamous cell carcinoma risk with chronic use. Suprapubic preferred over urethral for long-term use (fewer urethral complications). Change catheter every 4 weeks.

### Reflex Voiding/Condom Catheter (Males)
Triggered voiding using suprapubic tapping or other cutaneous stimulation. Requires adequate reflex detrusor contraction and low sphincter pressure. Condom catheter for external collection. Must confirm low-pressure voiding on urodynamics. Not recommended if DSD is present (high-pressure voiding).

### Credé and Valsalva Maneuvers
Manual suprapubic pressure (Credé) or abdominal straining (Valsalva). Used cautiously in LMN bladder only. Contraindicated in UMN bladder (worsens DSD, high-pressure voiding). Risk of vesicoureteral reflux.

<image>Bladder management algorithm for spinal cord injury by level and type of neurogenic bladder</image>

## Pharmacologic Management

### Antimuscarinics/Anticholinergics
Oxybutynin, tolterodine, solifenacin, darifenacin. Reduce detrusor hyperreflexia. Used with CIC to increase bladder capacity and reduce incontinence. Side effects: dry mouth, constipation, cognitive impairment (especially oxybutynin in elderly). Extended-release formulations better tolerated.

### Beta-3 Agonists
Mirabegron (Myrbetriq). Relaxes detrusor during storage phase. Alternative or adjunct to antimuscarinics. Fewer anticholinergic side effects. Monitor blood pressure.

### Alpha-Adrenergic Blockers
Tamsulosin, terazosin, doxazosin. Relax bladder neck and internal sphincter. Used in DSD to reduce outlet resistance. Side effects: orthostatic hypotension (especially problematic in SCI with baseline hypotension).

### Botulinum Toxin (OnabotulinumtoxinA)
Intradetrusor injection for refractory detrusor hyperreflexia. 200 units for neurogenic detrusor overactivity (FDA approved). Duration: 6-9 months. Effective for reducing incontinence and improving bladder capacity. Risk: urinary retention (must be willing to perform CIC).

## Urodynamic Evaluation
Essential for comprehensive bladder management. Measures: cystometric capacity, detrusor pressures, compliance, presence of DSD. Key parameters: Detrusor leak point pressure > 40 cmH2O = upper tract risk.

Bladder compliance < 12.5 mL/cmH2O = poor compliance, upper tract risk. Baseline urodynamics within 3-6 months of injury. Annual or biannual follow-up based on findings.

## Upper Tract Surveillance
Renal ultrasound at baseline and annually. Serum creatinine and GFR monitoring. Assess for hydronephrosis, renal calculi, renal scarring. Vesicoureteral reflux evaluation if indicated. Prompt treatment of hydronephrosis (catheter adjustment, urologic referral).

## Urinary Tract Infections
Distinguish bacteriuria from symptomatic UTI. Asymptomatic bacteriuria is universal with CIC - DO NOT TREAT. Symptomatic UTI: fever, increased spasticity, autonomic dysreflexia, cloudy/foul-smelling urine, malaise, new incontinence. Treatment: antibiotics guided by culture and sensitivity.

Prevention: adequate fluid intake, regular catheterization schedule, avoid over-distension. Cranberry products: no strong evidence for prevention. Methenamine hippurate: some evidence for prophylaxis.

<image>Long-term urologic surveillance protocol for spinal cord injury patients</image>

## Surgical Options
Augmentation cystoplasty: increases bladder capacity using bowel segment. Continent catheterizable channel (Mitrofanoff): abdominal stoma for catheterization when urethral access difficult. External sphincterotomy: reduces outlet resistance in UMN bladder (males with condom catheter). Sacral anterior root stimulator (Brindley procedure): electrical stimulation for voiding. Artificial urinary sphincter: selected cases.

## Clinical Pearls
The critical threshold is detrusor pressure > 40 cmH2O - this is the pressure above which upper tract damage occurs. Never treat asymptomatic bacteriuria in SCI patients on CIC - it leads to antibiotic resistance without clinical benefit. CIC volumes should be kept under 500 mL; if consistently higher, increase catheterization frequency or adjust fluid intake. In cervical SCI, bladder distension is a leading trigger for autonomic dysreflexia - a blocked catheter is a medical emergency. Early transition from indwelling to intermittent catheterization during inpatient rehabilitation reduces long-term urologic complications.

## References
- Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline. J Spinal Cord Med. 2006;29(5):527-573.
- Ginsberg D, et al. OnabotulinumtoxinA for neurogenic detrusor overactivity. J Urol. 2012;187(6):2131-2139.
- Pannek J, et al. Guidelines on neurogenic lower urinary tract dysfunction. European Association of Urology. 2023.
- Linsenmeyer TA. Catheter-associated urinary tract infections in persons with neurogenic bladders. J Spinal Cord Med. 2018;41(2):132-141.
- Cifu DX, et al. Braddom's Physical Medicine and Rehabilitation. 6th ed. Elsevier; 2020.